Michael Moeller Email & Phone Number

Philadelphia, Pa, Us

Monmouth Junction, New Jersey, United States

Providing consulting and advisory services for a company focused on 3D cell culture.

Greater Philadelphia

Providing business, manufacturing, and technical consulting services across the Cell & Gene Therapy, Biotherapeutic, Immunoassay Development, and Cell-Based Assay Fields.

New Jersey, United States

After stepping down as the CSO, I served as Senior Scientific Advisor supporting a number of projects, including a Phase I Clinical Trial involving autologous mesenchymal stem cells derived from patient adipose tissue.

New Jersey, United States

Products Created, Optimized, and Brought to Market:1. ACSelerateMAX™ Xeno-Free Human Mesenchymal Stem Cell Growth Medium (Marketed currently as "PeproGrow hMSC Medium" by PeproTech, Inc.)2. ACSelerate AD™ Adipogenic Differentiation Medium3. ACSelerate CY™ Chondrogenic Differentiation Medium4. ACSelerate OB™ Osteogenic Differentiation MediumTechnology Platforms Supported, Optimized, Characterized and Licensed:1. ATGRAFT™ Autologous Adipose Tissue Collection, Processing, and Storage2. AutokineCM™ Harvested Human Mesenchymal Stem Cell Secretome ProductionPatents Filed: 1. Human Serum for Cell Culture Medium for Clinical Growth of Human Adipose Stem Cells. Michael L. Moeller, PhD, Inventor2. Systems and Methods To Isolate and Expand Stem Cells from Urine. Michael L. Moeller, PhD, Inventor3. Systems and Methods for Preparation and Use of a DMSO-Free Cryopreservative and Ambient Temperature Mesenchymal Stem Cell Transport Medium. Michael L. Moeller, PhD, InventorAssays and Protocols Developed:1. Implementation of semi-quantitative histological criteria for the assessment of the tissue quality of incoming tissue samples2. Development and implementation of flow cytometric analytical templates for 8-parameter characterization of mesenchymal stem cells3. Development and implementation of a complete battery of Quality Control tests and procedures for a human cell therapy product and its production workflow4. Implementation and integrations of new technologies to production workflowOther Responsibilities:1. I drove the creation and development of FDA submissions, including an approved IND for an active Phase I Clinical Trial.

New Jersey, United States

New Jersey, United States

Drove the development and transformation of a cell and tissue storage commercial operation into a clinically-oriented company working to develop a full workflow for the collection of patient tissue followed by the isolation and expansion of client-specific mesenchymal stem cells. Under my direction, we optimized the cell culture media and expansion protocols to support large-scale customer cell expansions.

Swedesboro, New Jersey, United States

Working to build an exceptional business line of products and technologies to support the Cell & Gene Therapy field and advance the future of biological medicine.-Managed and worked to support a national $35M+ business segment through coordinated activities across marketing, category management, and sales teams-Led efforts to develop product catalogs and marketing literature to increase brand awareness-Led in the development and execution of matrixed strategies to achieve penetration in a nw market segment-Served as SME for Cell Biology, Cell & Gene Therapies, Stem Cells, Viral Vectors, and Bioprocessing-Drove strategic partnerships to enhance portfolio and to become a supplier to clients-Drove efforts to identify new business and potential customers-Provided training and technical support for sales representatives

New Jersey, United States

Development and maturation of a CRO focused on delivering the highest quality contract services to support cell & gene therapies. Worked with clients to design over $4.2M in research projects in 9 months, drove the addition of 50+ new assays to service catalog in 9 months, worked to develop web presence and marketing efforts, drove the development of internal collaborations with other Eurofins entities to provide end-to-end solutions for cell & gene therapy.

New Jersey, United States

Served as a scientific and technical lead and consultant for multiple organizations involved in cellular therapy and regenerative medicine.

New Jersey, United States

1. Worked through a matrixed interface of R&D, marketing, and external collaborators to develop, commercialize, and market a full product line of new cell culture media including media solutions for human pluripotent stem cells, human mesenchymal stem cells, and human neural stem cells. 2. Leveraged strategic partnerships with the ReMDO Consortium to develop “Universal Media” capable of supporting the expansion of most mesodermal, ectodermal, and endodermal cell types. This has included:A. Direct contributions to basal medium formulationsB. Direct contributions to cell type-specific “supplement pack” formulationsC. Data analysis leading to final formulationsD. Optimization of ECM coating/cell culture medium combinations to promote maximum growth of physiologically-relevant cellsE. Development of commercialization strategy3. Leveraged collaborations at Rutgers University to the develop and commercialize new and novel cell culture media for creating, expanding, and maintaining cultures of iPSC/ESC cells and iPSC-derived neural stem cells. 4. Leveraged collaboration with American CryoStem to commercialize a unique cell culture medium capable of supporting the rapid, large-scale expansion of physiologically-relevant human mesenchymal stem cells from multiple tissue sources.5. Leveraged expertise and external collaborations to address the development of novel extracellular matrix (ECM) products and applications.

New Jersey, United States

1. Contributed to and demonstrated personal initiative in multiple projects (see below) to better characterize a platform technology and workflow and to optimize platform performanceA. Flow cytometric assays to characterize output collection efficiency of target cellsB. Collection and efficiency QC assays to permit multiple unbiased comparative analyses of sequential iterations of technical platformC. Development and implementation of a battery of QC workflow protocols to assess and identify useful technical modifications2. Liaison between Janssen sites to coordinate transfer of project from the Research phase to Development phase3. Proven professional in project development and strategy called upon routinely to present data internally and externally and to present opinions concerning project direction4. Developed and validated a comprehensive series of flow cytometric-based QC assays5. Created test method qualification strategy for technical platform and workflow to be used by the Janssen Research Laboratories (JRL)

Colorado, United States

1. Contributed to and drove the significant expansion of East Coast business through strategic research liaisons, and informational seminars2. Provided significant technical training to customers3. Generated new technical literature to demonstrate instrument applications4. Leveraged relationships with external partners (including, but not limited to, CDC, USAMRIID, GeoVax, and NIH) to create accurate infective:total viral particle ratios for HIV, Hepatitis B, Herpes, Small Pox, Monkey Pox, and Ebola

Pennsylvania, United States

Facilitated customer success and sales growth through provision of on-site technical support and technical presentations and seminars. Matrixed with R&D and Marketing to develop, commercialize, and market the following products: 1. Oligodendrocyte Progenitor Cells (OPCs = Cat. #:CS204496) derived from H9 human embryonic stem cells2. Human OPC Expansion Media Kit (Cat. #: SCM107)3. Human OPC Spontaneous Differentiation Media Kit (Cat. #: SCM106)4. Human Oligodendrocyte Characterization Kit (SCR601)Contributed multiple detailed strategies for the creation and development of novel cell biological products and technologies, served as a key contributor to the development, growth, and success of a small business unit focused on the algal biofuels market, and served as a corporate trainer in cell and stem cell biology.

New Jersey, United States

Developed a number of approaches to drive the differentiation of human neural stem cells (hNSCs) to the oligodendrocyte progenitor cell (OPC) phenotype with intentions to explore the therapeutic applications of these cells in the alleviation of white matter disorders (leukodystrophies) such as Multiple Sclerosis.

New Jersey, United States

Co-directed New Jersey's first Stem Cell Training Course and conducted active research into feeder-free expansion strategies for human pluripotent stem cells, novel expansion and directed differentiation strategies for human placental mesenchymal stem cells, and phenotypic programming/directed differentiations of human neural stem cells.

California, United States

Conducted research into the molecular mechanisms underlying synaptic maturation, The goal of our work was to investigate mechanisms which, when perturbed, lead to the autism spectrum of neurological disorders.

1. Created a novel, published method for analyzing changes in phenotypic marker expressions in hollow cellular aggregates of human neural stem cells2. Created new approaches to the targeted differentiations of human neural stem cells into neurons3. Developed multiple new approaches to the expansion of human neural stem cells, including uses of rotating bioreactors4. Drove projects in the development and optimization of 6 novel artificial tissue model systems using extracellular matrix (ECM) proteins and primary cells harvested from native tissues:A. Artificial corneal modelB. Artificial nervous tissue model C. Artificial skin model D. Artificial dermal modelE. Artificial pericardial model (the “CardioPatch”) of proprietary design capable of being used following open-heart surgeryF. Artificial vascular models5. Drove the development and banking of multiple primary cell lines (modified and unmodified) from patient tissues6. Explored the use of Cre-Lox hTERT transgenes in the transient immortalizations of human cells

Doctor Of Philosophy - Phd, Molecular Biology And Immunology

Master Of Science - Ms, Biology (Invertebrate Zoology)

Bachelor Of Science - Bs, Biology, General